Group One Trading’s Avadel Pharmaceuticals AVDL Stock Holding History

Group One Trading’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-70,900	Closed	-$1.53M	–	7626
2025 Q4	$1.53M	Sell	70,900 -63,100	-47%	-$1.23M	﹤0.01%	2505
2025 Q3	$2.05M	Buy	134,000 +6,200	+5%	+$80.7K	﹤0.01%	2303
2025 Q2	$1.13M	Buy	127,800 +114,900	+891%	+$1.01M	﹤0.01%	2649
2025 Q1	$101K	Sell	12,900 -243,100	-95%	-$2.04M	﹤0.01%	4592
2024 Q4	$2.69M	Sell	256,000 -152,400	-37%	-$1.85M	0.01%	1655
2024 Q3	$5.36M	Buy	408,400 +86,100	+27%	+$1.31M	0.02%	964
2024 Q2	$4.53M	Buy	322,300 +122,300	+61%	+$1.99M	0.02%	867
2024 Q1	$3.38M	Buy	200,000 +79,700	+66%	+$1.19M	0.01%	1104
2023 Q4	$1.7M	Sell	120,300 -29,700	-20%	-$349K	﹤0.01%	2010
2023 Q3	$1.54M	Sell	150,000 -203,900	-58%	-$2.73M	0.01%	1870
2023 Q2	$5.83M	Buy	353,900 +56,300	+19%	+$732K	0.02%	844
2023 Q1	$2.73M	Sell	297,600 -38,300	-11%	-$315K	0.01%	1277
2022 Q4	$2.41M	Buy	335,900 +78,700	+31%	+$552K	0.01%	1670
2022 Q3	$1.29M	Buy	257,200 +164,100	+176%	+$903K	﹤0.01%	2309
2022 Q2	$227K	Buy	93,100 +15,400	+20%	+$63.2K	﹤0.01%	4168
2022 Q1	$531K	Sell	77,700 -47,400	-38%	-$326K	﹤0.01%	3743
2021 Q4	$1.01M	Buy	125,100 +78,300	+167%	+$716K	﹤0.01%	3350
2021 Q3	$459K	Sell	46,800 -305,500	-87%	-$2.41M	﹤0.01%	4291
2021 Q2	$2.37M	Sell	352,300 -201,800	-36%	-$1.6M	﹤0.01%	2459
2021 Q1	$5.01M	Buy	554,100 +513,800	+1,275%	+$4.15M	0.01%	1508
2020 Q4	$269K	Buy	40,300 +23,800	+144%	+$149K	﹤0.01%	3829
2020 Q3	$83K	Sell	16,500 -465,500	-97%	-$3.39M	﹤0.01%	4321
2020 Q2	$3.9M	Sell	482,000 -122,300	-20%	-$1.08M	0.02%	981
2020 Q1	$4.8M	Buy	604,300 +297,300	+97%	+$2.28M	0.04%	560
2019 Q4	$2.32M	Buy	307,000 +223,600	+268%	+$1.18M	0.02%	1180
2019 Q3	$347K	Buy	83,400 +75,400	+943%	+$189K	﹤0.01%	2643
2019 Q2	$23K	Buy	+8,000	New	+$13.8K	﹤0.01%	4116
2018 Q3	–	Sell	-51,300	Closed	-$314K	–	5170
2018 Q2	$314K	Sell	51,300 -9,100	-15%	-$63.8K	﹤0.01%	2685
2018 Q1	$440K	Buy	60,400 +59,400	+5,940%	+$523K	﹤0.01%	2155
2017 Q4	$8K	Buy	+1,000	New	+$9.38K	﹤0.01%	4434
2016 Q4	–	Sell	-3,000	Closed	-$37K	–	4405
2016 Q3	$37K	Buy	+3,000	New	+$39.2K	﹤0.01%	3502
2016 Q2	–	Sell	-30,600	Closed	-$338K	–	4596
2016 Q1	$338K	Sell	30,600 -6,500	-18%	-$64.6K	﹤0.01%	1973
2015 Q4	$453K	Buy	37,100 +34,000	+1,097%	+$530K	0.01%	1894
2015 Q3	$51K	Sell	3,100 -18,100	-85%	-$399K	﹤0.01%	3515
2015 Q2	$449K	Buy	21,200 +7,600	+56%	+$136K	0.01%	1873
2015 Q1	$245K	Buy	13,600 +6,800	+100%	+$106K	﹤0.01%	2219
2014 Q4	$116K	Sell	6,800 -12,700	-65%	-$181K	﹤0.01%	2729
2014 Q3	$279K	Sell	19,500 -16,400	-46%	-$236K	﹤0.01%	2101
2014 Q2	$539K	Buy	35,900 +2,400	+7%	+$28.9K	0.01%	1579
2014 Q1	$449K	Buy	33,500 +32,500	+3,250%	+$348K	0.01%	1719
2013 Q4	$8K	Hold	1,000	–	–	﹤0.01%	4672
2013 Q3	$7K	Sell	1,000 -1,100	-52%	-$6.77K	﹤0.01%	4612
2013 Q2	$13K	Buy	+2,100	New	+$10.8K	﹤0.01%	4318

Other funds holding AVDL

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Group One Trading's AVDL Position: Q1 2026 in Review

Group One Trading sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 93,028 shares — an estimated $2M sold.

Group One Trading first reported a position in AVDL in Q2 2013 and held it in 34 quarters. The position peaked at $2M in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

Group One Trading reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Group One Trading sold 93,028 Avadel Pharmaceuticals shares in Q1 2026, an estimated $2M.
Group One Trading first reported a position in Avadel Pharmaceuticals in Q2 2013 and held it in 34 quarters.
Group One Trading's Avadel Pharmaceuticals position peaked at $2M in Q4 2025.
2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.